Want to see FR:CLARI full AI Analyst Report?
Top Page
Clariane
(CLARI)
Select Model
Select Model
Rating:47Neutral
Price Target:
€3.50
▼(-7.89% Downside)
Action:Reiterated
Date:10/02/26
The score is held back primarily by elevated and worsening leverage alongside weak bottom-line profitability, despite steady operating margins and consistently positive free cash flow. Technicals also point to a weak downtrend with bearish momentum, and valuation appears stretched with a high P/E and no dividend yield support.
Positive Factors
Revenue growth and operating resilience
Strong revenue growth alongside relatively stable operating margins indicates resilient demand across Clariane’s care activities. This combination supports continued operating cash generation and suggests the core business can absorb growth investments while maintaining its earning capacity over the coming quarters.
Negative Factors
Worsening leverage
The sharp increase in debt-to-equity makes the balance sheet more sensitive to financing costs, earnings volatility, and any pressure on operating cash flow. Elevated leverage can restrict capital allocation and leave less financial flexibility to invest in facilities or manage weaker trading periods.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth and operating resilience
Strong revenue growth alongside relatively stable operating margins indicates resilient demand across Clariane’s care activities. This combination supports continued operating cash generation and suggests the core business can absorb growth investments while maintaining its earning capacity over the coming quarters.
Read all positive factors
Clariane (CLARI) vs. iShares MSCI France ETF (EWQ)
Market Cap
€1.16B
Dividend Yield5.75%
Average Volume (3M)449.20K
Price to Earnings (P/E)81.3
Beta (1Y)1.37
Revenue Growth0.99%
EPS GrowthN/A
CountryFR
Employees70,685
SectorGeneral
Sector StrengthN/A
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.04
Shares Outstanding357,540,860
10 Day Avg. Volume325,489
30 Day Avg. Volume449,204
Financial Highlights & Ratios
PEG Ratio-8.51
Price to Book (P/B)0.39
Price to Sales (P/S)0.26
P/FCF Ratio2.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.41
Revenue Forecast (FY)€5.39B
Clariane Business Overview & Revenue Model
Company Description
Clariane SE, established in Paris, France, in 2001 and known as Korian until its rebranding in June 2023, specializes in delivering comprehensive medical and non-medical care and support. The company serves senior citizens and individuals facing e...
How the Company Makes Money
Clariane primarily makes money by delivering care services and receiving payment for patient/resident stays and care interventions. The largest revenue stream typically comes from residential long-term care (e.g., nursing homes), where revenue is ...
Clariane Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
38
Negative
Cash Flow
66
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.35B | 5.31B | 5.28B | 5.00B | 4.44B | 4.14B |
| Gross Profit | 143.02M | 431.50M | 4.84B | 1.57B | 4.09B | 3.83B |
| EBITDA | 748.73M | 1.01B | 1.01B | 956.67M | 907.45M | 943.72M |
| Net Income | 12.61M | 1.60M | -55.12M | -105.25M | 22.06M | 91.11M |
Balance Sheet | ||||||
| Total Assets | 14.36B | 13.81B | 14.26B | 15.18B | 14.57B | 14.31B |
| Cash, Cash Equivalents and Short-Term Investments | 1.42B | 821.56M | 518.10M | 677.91M | 734.35M | 1.22B |
| Total Debt | 8.35B | 7.81B | 7.98B | 8.55B | 8.27B | 8.23B |
| Total Liabilities | 10.44B | 9.89B | 10.24B | 11.24B | 10.71B | 10.54B |
| Stockholders Equity | 3.62B | 3.61B | 3.69B | 3.58B | 3.54B | 3.49B |
Cash Flow | ||||||
| Free Cash Flow | 570.87M | 577.76M | 600.10M | 320.04M | 116.36M | 311.05M |
| Operating Cash Flow | 801.77M | 796.46M | 908.13M | 804.15M | 681.66M | 839.97M |
| Investing Cash Flow | 180.84M | 137.55M | 47.69M | -669.52M | -770.26M | -825.28M |
| Financing Cash Flow | -321.59M | -670.90M | -1.11B | -193.61M | -550.13M | 31.38M |
Clariane Technical Analysis
Negative
3.80
Price Trends
3.70
Negative
3.88
Negative
3.89
Negative
Market Momentum
-0.16
Positive
32.88
Neutral
30.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:CLARI, the sentiment is Negative. The current price of 3.8 is above the 20-day moving average (MA) of 3.31, above the 50-day MA of 3.70, and below the 200-day MA of 3.89, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 32.88 is Neutral, neither overbought nor oversold. The STOCH value of 30.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:CLARI.
Clariane Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | €249.04M | 9.68 | 7.63% | 7.95% | 10.06% | 21.64% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | €133.97M | 2.32 | 49.70% | 0.58% | -1.79% | 10979.07% | |
51 Neutral | €1.63B | -6.15 | -15.35% | 0.84% | 3.92% | 31.20% | |
49 Neutral | €986.63M | -16.18 | -4.25% | 11.04% | 2.65% | 10.71% | |
47 Neutral | €1.16B | 81.25 | 0.35% | 5.75% | 0.99% | ― |
* General Sector Average
FR:CLARI
Clariane
3.25
-0.75
-18.83%
FR:BLC
Bastide le Confort Medical
18.32
-6.48
-26.13%
FR:LNA
LNA Sante SA
23.90
1.11
4.87%
FR:EMEIS
Orpea SA
10.08
-5.63
-35.84%
FR:GDS
Ramsay Generale de Sante
8.94
0.02
0.22%
Clariane Corporate Events
Clariane Secures ESG-Linked €700m Revolving Credit Facility to Bolster Liquidity
Sep 21, 2026
Clariane has signed a new unsecured and unguaranteed 700 million euro revolving credit facility maturing in 2031, replacing its existing syndicated line and following a recently completed 500 million euro senior bond issue. The facility, which can...
Clariane Raises €500m in Oversubscribed Bond Issue and Secures New €700m Credit Line
Sep 8, 2026
Clariane has successfully placed €500 million of unsecured senior bonds maturing in 2032 at a 6.875% coupon, following strong oversubscription from institutional investors in France and abroad. The proceeds, combined with existing cash, will...
Clariane Launches €500 Million Note Offering and Secures New €700 Million Credit Facility
Sep 7, 2026
Clariane has launched a proposed offering of €500 million in euro-denominated senior notes due 2032 to refinance part of its existing debt. The proceeds, together with cash on hand, are earmarked to fully repay and cancel a €350 millio...
Clariane boosts half-year earnings and secures over €1bn in refinancing
Jul 29, 2026
Clariane reported first-half 2026 revenue of €2.699bn, up 4.6% organically, driven by volumes and pricing, with pre-IFRS 16 EBITDA rising 14.9% and margin improving to 10.4%. Opco EBITDA climbed 25.1% and margin reached 6.2%, while nursing h...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.